Publication: Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
dc.contributor.author | Opazo-Ríos, Lucas | |
dc.contributor.author | Mas, Sebastián | |
dc.contributor.author | Marín-Royo, Gema | |
dc.contributor.author | Mezzano, Sergio | |
dc.contributor.author | Gómez-Guerrero, Carmen | |
dc.contributor.author | Moreno, Juan Antonio | |
dc.contributor.author | Egido, Jesús | |
dc.contributor.authoraffiliation | [Opazo-Ríos,L; Mas,S; Marín-Royo,G; Gómez-Guerrero,C; Egido,J] Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain. [Mezzano,S] Laboratorio de Nefrología, Facultad de Medicina, Universidad Austral de Chile, Valdivia, Chile. [Moreno,JA] Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain. [Moreno,JA] Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Cordoba, Spain. [Moreno,JA] Hospital Universitario Reina Sofía, Cordoba, Spain. | |
dc.contributor.funder | This paper was not funded. The authors’ work has been supported by FEDER-ISCIII Funds (PI17/00130, PI17/01495, and SAF2015-63696-R), Spanish Ministry of Economy and Competitiveness (RTI2018-098788-B-100, DTS17/00203, DTS19/00093, and RYC-2017-22369), Fondecyt Project (No. 1160465), Spanish Society of Cardiology (SEC), Spanish Society of Nephrology (SEN), and Spanish Society of Atherosclerosis (SEA). There are no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. | |
dc.date.accessioned | 2022-05-03T12:33:02Z | |
dc.date.available | 2022-05-03T12:33:02Z | |
dc.date.issued | 2020-04-10 | |
dc.description.abstract | Lipotoxicity is characterized by the ectopic accumulation of lipids in organs different from adipose tissue. Lipotoxicity is mainly associated with dysfunctional signaling and insulin resistance response in non-adipose tissue such as myocardium, pancreas, skeletal muscle, liver, and kidney. Serum lipid abnormalities and renal ectopic lipid accumulation have been associated with the development of kidney diseases, in particular diabetic nephropathy. Chronic hyperinsulinemia, often seen in type 2 diabetes, plays a crucial role in blood and liver lipid metabolism abnormalities, thus resulting in increased non-esterified fatty acids (NEFA). Excessive lipid accumulation alters cellular homeostasis and activates lipogenic and glycogenic cell-signaling pathways. Recent evidences indicate that both quantity and quality of lipids are involved in renal damage associated to lipotoxicity by activating inflammation, oxidative stress, mitochondrial dysfunction, and cell-death. The pathological effects of lipotoxicity have been observed in renal cells, thus promoting podocyte injury, tubular damage, mesangial proliferation, endothelial activation, and formation of macrophage-derived foam cells. Therefore, this review examines the recent preclinical and clinical research about the potentially harmful effects of lipids in the kidney, metabolic markers associated with these mechanisms, major signaling pathways affected, the causes of excessive lipid accumulation, and the types of lipids involved, as well as offers a comprehensive update of therapeutic strategies targeting lipotoxicity. | es_ES |
dc.description.version | Yes | es_ES |
dc.identifier.citation | Opazo-Ríos L, Mas S, Marín-Royo G, Mezzano S, Gómez-Guerrero C, Moreno JA, et al. Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities. Int J Mol Sci. 2020 Apr 10;21(7):2632 | es_ES |
dc.identifier.doi | 10.3390/ijms21072632 | es_ES |
dc.identifier.essn | 1422-0067 | |
dc.identifier.pmc | PMC7177360 | |
dc.identifier.pmid | 32290082 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10668/3610 | |
dc.journal.title | International Journal of Molecular Sciences | |
dc.language.iso | en | |
dc.page.number | 30 p. | |
dc.publisher | MDPI | es_ES |
dc.relation.publisherversion | https://www.mdpi.com/1422-0067/21/7/2632/htm | es_ES |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Lipotoxicity | es_ES |
dc.subject | Obesity | es_ES |
dc.subject | Type 2 diabetes | es_ES |
dc.subject | Fatty kidney | es_ES |
dc.subject | Diabetic nephropathy | es_ES |
dc.subject | Chronic kidney disease | es_ES |
dc.subject | Obesidad | es_ES |
dc.subject | Diabetes mellitus tipo 2 | es_ES |
dc.subject | Ácidos grasos | es_ES |
dc.subject | Riñón | es_ES |
dc.subject | Nefropatías diabéticas | es_ES |
dc.subject | Insuficiencia renal crónica | es_ES |
dc.subject.mesh | Medical Subject Headings::Anatomy::Tissues::Connective Tissue::Adipose Tissue | es_ES |
dc.subject.mesh | Medical Subject Headings::Organisms::Eukaryota::Animals | es_ES |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Biological Factors::Biological Markers | es_ES |
dc.subject.mesh | Medical Subject Headings::Diseases::Endocrine System Diseases::Diabetes Mellitus::Diabetes Complications::Diabetic Nephropathies | es_ES |
dc.subject.mesh | Medical Subject Headings::Health Care::Health Services Administration::Patient Care Management::Disease Management | es_ES |
dc.subject.mesh | Medical Subject Headings::Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Lipid Metabolism Disorders::Dyslipidemias | es_ES |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Lipids::Fatty Acids::Fatty Acids, Nonesterified | es_ES |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Carbohydrates::Polysaccharides::Glucans::Glycogen | es_ES |
dc.subject.mesh | Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans | es_ES |
dc.subject.mesh | Medical Subject Headings::Anatomy::Urogenital System::Urinary Tract::Kidney | es_ES |
dc.subject.mesh | Medical Subject Headings::Anatomy::Cells::Cellular Structures::Intracellular Space::Cytoplasm::Cytoplasmic Structures::Organelles::Mitochondria | es_ES |
dc.subject.mesh | Medical Subject Headings::Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity | es_ES |
dc.subject.mesh | Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis | es_ES |
dc.subject.mesh | Medical Subject Headings::Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Signal Transduction | es_ES |
dc.subject.mesh | Medical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Susceptibility | es_ES |
dc.subject.mesh | Medical Subject Headings::Phenomena and Processes::Metabolic Phenomena::Metabolism::Lipid Metabolism | es_ES |
dc.title | Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities | es_ES |
dc.type | review article | |
dc.type.hasVersion | VoR | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- OpazoRios_LipotoxicityAnd.pdf
- Size:
- 2.43 MB
- Format:
- Adobe Portable Document Format
- Description:
- Revisión